IFW

MAY 1 2 2005 E

Attorney Docket No: 28967/37564B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Alitalo et al.

Serial No.: 10/669,176

Filed: September 23, 2003

For: VEGF-C or VEGF-D Materials and Methods for Treatment of

Neuropathologies

I hereby certify that this paper is being
deposited with the United States Postal
Service with sufficient postage as first class
mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

May 10, 2005

Katherine L. Neville

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The patents and/or publications listed on the enclosed PTO Form-1449 are submitted pursuant to 37 CFR §§ 1.56, 1.97, and 1.98. Copies of the patents or publications are enclosed. The applicants request that the examiner consider the documents and make them of record in the application.

Documents A1-A9, B1-B9, and C1-C62 were submitted in related U.S. Application No. 10/262,538. All other non-U.S. patent documents are submitted herewith.

In accordance with 37 CFR §1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. In accordance with 37 CFR §1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

The Information Disclosure Statement is submitted before receipt of the first Office Action in the above-mentioned application and as such, no fee is required in connection with filing of this paper.

Please charge any deficiency to Marshall Gerstein and Borun LLP Deposit Account No. 13-2855.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

- ENICC

6300 Sears Tower

233 South Wacker Drive

Chicago, Illinois 60606-6357

(312) 474-6300

By:

Katherine L. Neville Registration No. 53,379

May 10, 2005 Agent for Applicants

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No. 28967/37564B Serial No. 10/669,176

Applicant

Alitalo et al.

Filing Date 09-23-03

1647

Group

INFORMATION DISCLOSURE MAY 1 2 2005 **STATEMENT**

RADEMARY	1			T DOCUMEN	N12		TEN E
*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	5,607,918	03/04/97	Eriksson et al.			
	A2	5,776,755	07/07/98	Alitalo et al.			
	A3	5,840,693	11/24/98	Eriksson et al.			
	A4	6,130,071	10/10/00	Alitalo et al.			
	A5	6,221,839	04/24/01	Alitalo et al.			
	A6	6,235,713	05/22/01	Achen et al.			
	A7	6,245,530	06/12/01	Alitalo et al.			
	A1	5,932,540	08/03/99	Hu et al.	514	2	·
	A2	5,935,820	08/10/99	Hu et al.	435	69.4	
	A3	5,952,199	09/14/99	Davis-Smyth	435	69.7	
	A4	6,040,157	03/21/00	Hu et al.	435	69.4	\$1
	A5	6,100,071	08/08/00	Davis-Smyth	435	69.7	
	A6	6,107,046	08/22/00	Alitalo et al.	435	7.1	7
· .	A7	6,331,302	12/18/01	Bennett	424	146.1	1.
	A8	6,361,946	03/26/02	Alitalo et al.	435	6	
	A9	6,383,484	05/07/02	Achen et al.	424	133.1	
	A10	6,383,486	05/07/02	Davis-Smyth	424	158.1	
	A11	6,403,088	06/11/02	Alitalo	424	139.1	
	A12	6,451,764	09/17/02	Lee et al.	514	12	
	A13	6,576,608	06/10/03	Lee et al.	514	2	
	A14	6,608,182	08/19/03	Rosen et al.	530	399	
	A15	6,645,933	11/11/03	Alitalo et al.	514	2	
	A16	6,673,343	01/06/04	Bennett et al.	424	133.1	
	A17	6,689,580	02/10/04	Achen et al.	435	69.1	
	A18	6,730,489	05/04/04	Achen et al.	435	7.1	
	A19	6,730,658	05/04/04	Alitalo et al.	514	12	
	A20	2001/0038842	11/08/01	Achen et al.			03-02-200
· · · · · · · · · · · · · · · · · · ·	A21	2002/0065218	05/30/02	Achen et al.		. 	01-18-200

EXAMINER

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No. Serial No. 28967/37564B Applicant

INFORMATION DISCLOSURE **STATEMENT**

10/669,176 Alitalo et al. Filing Date Group 09-23-03 1647

A22	2002/0102260	08/01/02	Achen et al.		09-20-2001
A23	2002/0120123	08/29/02	Rosen et al.		04-23-2002
A24	2002/0123481	09/05/02	Oliviero, S.		05-07-2002
A25	2002/0127222	09/12/02	Achen et al.		12-23-1998
A26	2002/0146420	10/10/02	Bennett et al.		10-17-2001
A27	2002/0151489	10/17/02	Gavereaux et al.		10-02-2001
A28	2002/0182683	12/05/02	Hu et al.		02-01-2002
A29	2002/0197691	12/26/02	Sugiyama, J.		04-29-2002
A30	2003/0008357	01/09/03	Hu et al.		08-24-2001
A31	2003/0028007	02/06/03	Hu et al.		02-28-2002
A32	2003/0091567	05/15/03	Alitalo et al.		07-23-2002
A33	2003/0092604	05/15/03	Alitalo et al.		07-23-2002
A34	2003/0125537	07/03/03	Achen et al.		06-05-2002
A35	2003/0166523	09/04/03	Achen et al.		05-03-2001
A36	2003/0166547	09/04/03	Oliviero, S.		06-19-2002
A37	2003/0166873	09/04/03	Lee et al.		01-17-2003
A38	2003/0170786	09/11/03	Rosen et al.		04-12-2002
A39	2003/0175274	09/18/03	Rosen et al.		04-12-2002
A40	2003/0176674	09/18/03	Rosen et al.		04-12-2002
A41	2003/0180294	09/25/03	DeVries, G.		02-22-2002
A42	2003/0211101	11/13/03	Wise et al.		01-28-2003
A43	2003/0211988	11/13/03	Epstein, S.		02-14-2003
A44	2003/0215921	11/20/03	Coleman, T.		08-03-2001
A45	2003/0228283	12/11/03	Heinzerling et al.		04-29-2003
A46	2003/0232437	12/18/03	Zhang et al.		06-17-2002
A47	2004/0037820	02/26/04	Alitalo et al.		01-19-2001
A48	5,196,315	03/23/93	Ronnett et al.		
A49	5,654,183	08/05/97	Anderson et al.		
A50	2002/0045261	4/18/02	Snyder et al.		02/28/01
A51	2003/0040023	2/27/03	Klassen et al.		04/22/01
		L .			
	A23 A24 A25 A26 A27 A28 A29 A30 A31 A32 A33 A34 A35 A36 A37 A38 A39 A40 A41 A42 A43 A44 A45 A46 A47 A48 A49 A50	A232002/0120123A242002/0123481A252002/0127222A262002/0146420A272002/0151489A282002/0182683A292002/0197691A302003/0008357A312003/0028007A322003/0091567A332003/0092604A342003/0125537A352003/0166523A362003/0166547A372003/0166873A382003/0170786A392003/0175274A402003/0176674A412003/0180294A422003/0211101A432003/0215921A452003/0232437A462003/0232437A472004/0037820A485,196,315A495,654,183A502002/0045261	A23 2002/0120123 08/29/02 A24 2002/0123481 09/05/02 A25 2002/0127222 09/12/02 A26 2002/0146420 10/10/02 A27 2002/0151489 10/17/02 A28 2002/0182683 12/05/02 A29 2002/0197691 12/26/02 A30 2003/0028007 02/06/03 A31 2003/0028007 02/06/03 A32 2003/0091567 05/15/03 A33 2003/0092604 05/15/03 A34 2003/0125537 07/03/03 A35 2003/0166523 09/04/03 A36 2003/0166547 09/04/03 A37 2003/0166547 09/18/03 A40 2003/0170786 09/11/03 A39 2003/0176674 09/18/03 A41 2003/0211101 11/13/03 A42 2003/0211988 11/13/03 A43 2003/0228283 12/11/03 A44 2003/0232437 12/18/03 A45 <td>A23 2002/0120123 08/29/02 Rosen et al. A24 2002/0123481 09/05/02 Oliviero, S. A25 2002/0127222 09/12/02 Achen et al. A26 2002/0146420 10/10/02 Bennett et al. A27 2002/0151489 10/17/02 Gavereaux et al. A28 2002/0197691 12/26/02 Sugiyama, J. A30 2003/008357 01/09/03 Hu et al. A31 2003/0028007 02/06/03 Hu et al. A32 2003/0091567 05/15/03 Alitalo et al. A33 2003/0092604 05/15/03 Alitalo et al. A34 2003/0125537 07/03/03 Achen et al. A35 2003/0166523 09/04/03 Achen et al. A36 2003/0166547 09/04/03 Lee et al. A38 2003/0170786 09/11/03 Rosen et al. A40 2003/0175274 09/18/03 Rosen et al. A41 2003/021988 11/13/03 Epstein, S. A42</td> <td>A23 2002/0120123 08/29/02 Rosen et al. A24 2002/0123481 09/05/02 Oliviero, S. A25 2002/0127222 09/12/02 Achen et al. A26 2002/0146420 10/10/02 Bennett et al. A27 2002/0151489 10/17/02 Gavereaux et al. A28 2002/0182683 12/05/02 Hu et al. A29 2002/0197691 12/26/02 Sugiyama, J. A30 2003/0008357 01/09/03 Hu et al. A31 2003/0028007 02/06/03 Hu et al. A32 2003/0092604 05/15/03 Alitalo et al. A33 2003/0125537 07/03/03 Achen et al. A34 2003/0166523 09/04/03 Achen et al. A35 2003/0166547 09/04/03 Lee et al. A37 2003/0166873 09/04/03 Rosen et al. A38 2003/017786 09/11/03 Rosen et al. A40 2003/0180294 09/25/03 DeVries, G. A42</td>	A23 2002/0120123 08/29/02 Rosen et al. A24 2002/0123481 09/05/02 Oliviero, S. A25 2002/0127222 09/12/02 Achen et al. A26 2002/0146420 10/10/02 Bennett et al. A27 2002/0151489 10/17/02 Gavereaux et al. A28 2002/0197691 12/26/02 Sugiyama, J. A30 2003/008357 01/09/03 Hu et al. A31 2003/0028007 02/06/03 Hu et al. A32 2003/0091567 05/15/03 Alitalo et al. A33 2003/0092604 05/15/03 Alitalo et al. A34 2003/0125537 07/03/03 Achen et al. A35 2003/0166523 09/04/03 Achen et al. A36 2003/0166547 09/04/03 Lee et al. A38 2003/0170786 09/11/03 Rosen et al. A40 2003/0175274 09/18/03 Rosen et al. A41 2003/021988 11/13/03 Epstein, S. A42	A23 2002/0120123 08/29/02 Rosen et al. A24 2002/0123481 09/05/02 Oliviero, S. A25 2002/0127222 09/12/02 Achen et al. A26 2002/0146420 10/10/02 Bennett et al. A27 2002/0151489 10/17/02 Gavereaux et al. A28 2002/0182683 12/05/02 Hu et al. A29 2002/0197691 12/26/02 Sugiyama, J. A30 2003/0008357 01/09/03 Hu et al. A31 2003/0028007 02/06/03 Hu et al. A32 2003/0092604 05/15/03 Alitalo et al. A33 2003/0125537 07/03/03 Achen et al. A34 2003/0166523 09/04/03 Achen et al. A35 2003/0166547 09/04/03 Lee et al. A37 2003/0166873 09/04/03 Rosen et al. A38 2003/017786 09/11/03 Rosen et al. A40 2003/0180294 09/25/03 DeVries, G. A42

EXAMINER

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.	Serial No.
28967/37564B	10/669,176
Applicant	

INFORMATION DISCLOSURE STATEMENT

Alitalo et al. Filing Date Group 09-23-03 1647

Examiner		Document	Publication	Country	Class	Subclass	Tra	inslation
Initials		Number	Date				Yes	No
	B1	WO 00/21560	04/20/00	PCT				
	B2	WO 00/23565	04/27/00	PCT				
	В3	WO 00/25805	05/11/00	PCT				
	B4	WO 01/09157	02/08/01	PCT				
····	B5	WO 01/31346	05/03/01	PCT				_
	B6	WO 96/26736	09/06/96	PCT				<u> </u>
	B7	WO 98/07832	02/26/98	PCT				
	B8	WO 98/33917	08/06/98	PCT			-	
	B9	WO 99/29729	06/17/99	PCT				ļ
	B10	EP 0935001	08/11/99	EPO		-		
	B11	WO 97/12972	04/10/97	PCT	-			<u>.</u>
	B12	WO 98/02543	01/22/98	PCT			. \$	
	B13	WO 00/45835	08/10/00	PCT				
	B14	WO 2004/009773	01/29/04	PCT			7	
	. (OTHER DOCUMEN	NTS (Including	Author, Title, D	ate, Pertin	ent Pages, e	tc.)	<u>.l</u>
	C1	Achen et al., "Mono interactions with bo 267:2505-2515, 200	clonal antibooth VEGF rece	lies to vascula	r endothe	lial growt	h factor-D	
	C2	Achen, et al., "Vasc tyrosine kinases VE Acad. Sci. U.S.A., 9	GF receptor 2	(flk1) and VI				
	C3	Bagnard et al., "Sen mediates migration shared receptor" J. 1	and apoptosis	of neural prog	genitor ce	lls by the		
	C4	Bellomo et al., "Mic (Vegfb) Have Small	er Hearts, Dys		ronary V	asculature		
		Recovery From Car						
	C5	Breiteneder-Geleff of Blood and Lymphat	et al., "Angios					ypes of
	C5 C6	Breiteneder-Geleff	et al., "Angios ic Capillaries' pilin-2, a Nove or the Semapho	Am. J. Pathoel Member of	1., 154(2) the Neuro	:385-394, pilin Fam	1999 ily, Is a Hi	gh

EXAMINER

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1647

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.	Serial No.
28967/37564B	10/669,176
Applicant	
Alitalo et al.	
Filing Date	Group

09-23-03

INFORMATION DISCLOSURE STATEMENT

		FORI	EIGN PATEN		NTS				
Examiner Initials		Document Number	Publication Date	Country	Class	Subclass		Translation	
					ļ.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Yes	No	
	C8	Cohen et al., "Neuro Biochem. Biophys.				Tract Exp	ress Nei	ıropilin-2"	
	C9 De Vries et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endo Growth Factor" Science 255:989-991, 1992						ndothelial		
	C10	Dumont et al., "Caro Receptor-3" Science			Embryo	s Deficie	nt in VE	GF	
	C11	Ferrara, J., "Molecu J Mol Med 77:527-5		al properties	of vascu	lar endoth	elial gro	owth factor	
	C12	Fujisawa et al., "Red biology 8:587-592,		psing/semapl	norins"]	Neuronal	and Glia	al cell	
-	C13		Fujisawa et al., "Roles of a neuronal cell-surface molecule, neuropilin, in nerve fiber fasciculation and guidance" Cell Tissue Res. 290:465-470, 1997						
	C14 Gagnon et al., "Identification of a natural soluble neuropilin-1 that binds vascul endothelial growth factor: <i>In vivo</i> expression and antitumor activity" Proc. Natl Sci USA 97(6):2573-2578, 2000								
	C15	Basis of Receptor Function and Specificity" Neuron 21:1079-1092, 1998 Giger et al., "Neuropilin-2 Is Required In Vivo for Selective Axon Guidance Responses to Secreted Semaphorins" Neuron, 25:29-41, 2000							
	C16					cė			
	C17					Placenta			
	C18 Hauser et al., "A Heparin-Binding Form of Placenta Growth Factor (PIGF-2 Expressed in Human Umbilical Vein Endothelial Cells and in Placenta" Growth Factors 9:259-268, 1993			•					
	C19	He et al., "Neuropilin Is a Receptor for the Axonal Chemorepellent Semaphorin III Cell 90:739-751. 1997				horin III"			
	C20	Hirsch et al., "Distri 823:67-79, 1999	bution of semap	phoring IV in	adult hu	man brair	" Brain	Res.	
	C21	Jeltsch et al., "Hype Science, 276:1423-1		hatic Vessels	in VEG	F-C Trans	sgenic N	Aice,"	
	C22	Joukov et al., "A No the Flt4 (VEGFR-3) 290-298 1996				-	-	_	
-	C23	Joukov et al., "Prote VEGF-C," EMBO J	•	-	Receptor	Specifici	ty and A	Activity of	

EXAMINER

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1647

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney Docket No.	Serial No.
28967/37564B	10/669,176
Applicant	
Alitalo et al.	·
Filing Date	Group

09-23-03

INFORMATION DISCLOSURE STATEMENT

		FORI	EIGN PATEN	I DOCUME	NTS			
*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Tr: Yes	anslation No
	C24	Joukov et al., "Vasc of Cell Physiol 173:		l Growth Fac	tors FEC	F-B and	VEGF-C" J	
	C25	by Antibodies again	Jussila et al., "Lymphatic Endothelium and Kaposi's Sarcoma Spindle Cells Detected by Antibodies against in Vascular Endothelial Growth Factor Receptor-3 ¹ " Cancer Res. 58:1599-1604, 1998					
	C26 Kaipainen et al., "Expression of the FMS-Like Tyrosine Kinase 4 Gene Become Restricted to Lymphatic Endothelium During Development," <i>Proc. Natl. Acad. USA</i> , 92:3566-3570 1995							
	C27		Karkkainen et al., "Lymphatic endothelium: a new frontier of metastasis research" Nature Cell Biology 4:E2-E5, 2002					
	C28	Karkkainen et al., "Missense mutations interfere with VEGFR-3 signalling in prima lymphoedema" Nat. Genet. 25:153-59, 2000						primary
	C29	Kawasaki et al., "A Development 126:4			in embr	yonic ves	sel formation	on"
-	C30	Kitsukawa et al., "Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs" Development, 121:4309-4318, 1995						
•	C31	Kolodkin et al., "Ne	uropilin Is a Se	maphorin III	Recepto	r" Cell 90	:753-762, 1	997
	C32	Maglione et al., "Tw growth factor (PIGF Oncogene 8:925-93), are transcribe					acenta
	C33	Makinen et al., "Inh transgenic mice exp						
	C34	Makinen et al., "Dif and Proteolytic Isofo						
	C35	Matthews et al., "A enriched primitive h Proc Natl Acad Sci	ematopoietic ce	ells and exhib				
	C36	Meyer et al., "A nov VEGF-E, mediates a VEGFR-1 (Flt-1) re	ingiogenesis vi	a signaling th	rough V	EGFR-2 (KDR) but 1	•
	C37	Miao et al., "Neurop progression" FASEI	-	•	ells pror	notes tum	or angioger	nesis and
	C38	Migdal et al., "Neuro 273:(35)22272-2227	_	centa Growtl	1 Factor-	2 Recepto	or*" J. Biol	. Chem.
	C39	Neufeld et al., "Vaso J 13:9-22 1999	cular endothelia	l growth fact	or (VEG	F) and its	receptors"	FASEB

EXAMINER DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce

Attorney Docket No. Serial No. 28967/37564B 10/669,176

INFORMATION DISCLOSURE **STATEMENT**

Applicant Alitalo et al. Filing Date Group 09-23-03 1647

	,	FO	REIGN PATEN		·			
Examiner Initials		Document Number	Publication Date	Country	Class	Subclass		Translation
							Yes	No
	C40	Olofsson et al., "V endothelial cell" P			•	_	wth fact	or for
· · · · · ·	C41	Ortega et al., "Sig	nal Relays in the	VEGF System	n" Fron	Biosci 4:1	41-152,	1999.
	C42	Pajusola et al., "Si tyrosine kinase rel						
	C43 Partanen et al., "VEGF-C and VEGF-D expression in neuroendocrine cel receptor, VEGFR-3, in fenestrated blood vessels in human tissues" <i>FASE</i> 2096, 2000							
	C44 Pasterkamp et al., "Emerging roles for semaphorins in neural regeneration" E Rev. 35:36-54, 2001						Brain Res	
	C45 Pavelock et al., "Differential Expression and Regulation of the Vascular En Growth Factor Receptors Neuropilin-1 and Neuropilin-2 in Rat Uterus*" Endocrinology 142:613-622, 2001					ndothelial		
C46 Petrova et al., "Signaling via Vascular Endothelial Res 253:117-130, 1999					al Growth Factor Receptors" Exp Ce			
	C47 Prevo et al., "Mouse LYVE-1 Is an Endocytic Receotor for Hyaluronan Endothelium" Biol. Chem. 276:(22) 19420-19430, 2001					onan in	Lymphatic	
	C48	Robinson et al., "The splice variants of vascular endothelial growth factor (Variants receptors" J. Cell Science 114:853-865, 2001					(VEGF) an	
	C49	Rossignol et al., "Human Neuropilin-1 and Neuropilin-2 Map to 10p12 and 2q34, Respectively" Genomics 57:459-460, 1999						
	C50 Rossignol et al., "Genomic Organization of Human Neuropilin-1 and Neuropilin Genes: Identification and Distribution of Splice Variants and Soluble Isoforms' Genomics 70:211-22, 2000 C51 Soker et al., "Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor" Cell 92:73				•			
	C52	Sondell et al., "Va Stimulates Axonal Proliferation in the 19(14):5731-5740	Outgrowth, Enl Peripheral Ner	nancing Cell S	urvival	and Schwa	ann Cell	•
	C53	Sondell et al., "Va stimulates axonal Neuroscience, 12:	outgrowth throu	gh the flk-1 re				
	C54	Stacker et al., "The Vascular Develop				Family: S	ignalling	g for

EXAMINER DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1647

Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Filing Date

09-23-03

Attorney Docket No. 28967/37564B Serial No. 10/669,176

Applicant Alitalo et al.

Group

INFORMATION DISCLOSURE STATEMENT

C55	Taipale et al., "Vascular Endothelial Growth Factor Receptor-3" Curr Top Microbiol Immunol 237:85-96 (1999).
C56	Takagi et al., "The A5 Antigen, a Candidate for the Neuronal Recognition Molecule, Has Homologies to Complement Components and Coagulation Factors" Neuron 7:295-307, 1991
C57	Tamagnone et al., "Signalling by semaphoring receptors: cell guidance and beyond" Trends in Cell Biol, 10:377-383, 2000
C58	Terman et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor" Biochem Biophys Res Comm 187:1579-1586, 1992
C59	Thompson et al., "PTP-e, a tyrosine phosphatase expressed in endothelium, negatively regulates endothelial cell proliferation" Am. J. Phsiol. Heart Circ. Physiol., 281:H396-H403, 2001
C60	Whitaker et al., "Vascular Endothelial Growth Factor Receptor-2 and Neuropilin-1 Form a Receptor Complex that is Responsible for the Differential Signaling Potency of VEGF ₁₆₅ and VEGF ₁₂₁ *" J. Bio Chem. 276:25520-25531, 2001
C61	Zachary, "Vascular endothelial growth factor" Intl J Biochem Cell Bio 30:1169-1174 1998
C62	Bernardi et al., "Respiratory and Cerebrovascular Responses to Hypoxia and Hypercapnia in Familial Dysautonomia", <i>Am. J. Respir. Crit. Care Med.</i> 167: 141-149, 2003
C63	Bjorklund et al., "Embryonic Stem Cells Develop into Functional Dopaminergic Neurons After Transplantation in a Parkinson Rat Model", <i>Proc. Natl. Acad. Sci</i> 99: 2344-2349, 2002
C64	Brown et al., "Multiplex Three-Dimensional Brain Gene Expression Mapping in a Mouse Model of Parkinson's Disease", <i>Genome Res.</i> 12: 868-884, 2002
C65	Crocker et al., "Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in a MPTP Mouse Model of Parkinson's Disease", J. Neurosci 23: 4081-4091, 2003
C66	Enholm et al., "Adenoviral Expression of Vasular Endothelial Growth Factor-C Induces Lymphangiogensis in the Skin", <i>Circ. Res.</i> 88: 623-629, 2001
C67	Facchiano et al., "Promotion of Regeneration of Corticospinal Tract Axons in Rats with Recombinant Vascular Endothelial Growth Factor Alone and Combined with Adenovirus Coding for this Factor", J. Neurosurg. 97: 161-168, 2002
C68	Gage et al., "Survival and Differentiation of Adult Neuronal Progenitor Cells Transplanted to the Adult Brain", <i>Proc. Natl. Acad. Sci. U.S.A.</i> 92: 11879-11883, 1995
C69	Gage et al., "Isolation, Characterization & Utilization of CNS Stem Cells", Ann Rev Neurosci 18: 159-192, 1995
C70	Gorio, et al., "Recombinant Human Erythropoietin Counteracts Secondary Injury and Markedly Enhances Neurological Recovery from Experimental Spinal Cord Trauma", <i>Proc. Natl. Acad. Sci.</i> 99: 9450-9455, 2002

EXAMINER

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce Patent and Trademark Office

	Tage 0 01 7
Attorney Docket No.	Serial No.
28967/37564B	10/669,176
Applicant	
Alitalo et al.	
Filing Date	Group
09-23-03	1647

INFORMATION DISCLOSURE STATEMENT

C71	Hartman et al., "Apolipoprotein E4 Influences Amyloid Deposition but not Cell Loss After Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease", <i>J. Neurosci</i> 22: 10083-10087, 2002
C72	Hickey et al., "Apoptosis in Huntington's Disease", Prog. Neuropsychopharmacol Biol Psychiatry 27: 255-265, 2003
C73	Kaushal et al., "Functional Small-Diameter Neovessels Created Using Endothelial Progenitor Cells Expanded Ex Vivo", Nat. Med. 7:1035-1040, 2001
C74	Kukk et al., "VEGF-C Receptior Binding and Pattern of Expression with VEGFR-3 Suggests a Role in Lymphatic Vascular Development", <i>Development</i> 122: 3829-3837, 1996
C75	Konobu et al., "The hNT Human Neuronal Cell Line Survives and Migrates into Rat Retina", Cell Transplantation 7: 549-558, 1998
C76	Krassioukov et al., "Episodic Hypertension Due to Autonomic Dysreflexia in Acute and Chronic Spinal Cord-Injured Rats", Am J. Physiol. 268: H2077-H2083, 1995
C77	Lacorraza et al., "Expression of Human β-Hexosaminidase α-subunit Gene (the Gene Defect of Tay-Sachs Disease) in Mouse Brains Upon Engraftment of Transduced Progenitor Cells", <i>Nature Med.</i> 4: 424-429, 1996
C78	Laitinen et al., "Adenovirus-Mediated Gene Transfer to Lower Limb Artey of Patients with Chronic Critical Leg Ischemia", <i>Hum. Gene. Ther.</i> 9: 1481-1486, 1998
C79	Lamarre-Cliche et al., "Octreotide for Orthostatic Hypotension", Can J. Clin Pharmacol 6: 213-215, 1999
C80	Mak et al., "The Holmes-Adie Plus Syndrome", J Clin Neurosci 7:452, 2000
C81	McKay, "Stem Cells in the Central Nervous System", Science, 276:66-71, 1997
C82	Nakatomi et al., "Regeneration of Hippocampal Pyramidal Neurons after Ischemic Brain Injury by Recruitment of Endogenous Neural Pregenitors", <i>Cell</i> 110: 429-441, 2002
C83	Oliver et al., "Prox 1, a prospero-related Homebox Gene Exprssed During Mouse Development", Mech. Dev. 44: 3-16, 1993
C84	Patel et al., "Acquired Horner's Syndrome: Clinical Review", <i>Optomery</i> 74: 245-256, 2003
C85	Picard-Riera et al., "Experimetnal Autoimmune Encephalomyelitis Mobilizes Neural Progenitors from the Subventricular Zone to Undergo Oligodendrogenesis in Adult Mice", <i>Proc. Natl. Acad. Sci. USA</i> 99: 13211-13216, 2002
C86	Puumalainen et al., "β-galactosidase Gene Transfer to Human Malignant Glioma In Vivo Using Replication-Deficient Retroviruses and Adenoviruses", Hum. Gene. Ther. 9: 1769-1774, 1998
C87	Quinn et al., "Inflammaton and Cerebral Amyloidosis are Disconnected in an Animal Model of Alzheimer's Disease", <i>J. Neuroimmunol.</i> 137: 32-41, 2003
	•

EXAMINER

U.S. Department of Commerce Patent and Trademark Office Attorney Docket No. Serial No. 28967/37564B 10/669,176 Applicant

INFORMATION DISCLOSURE **STATEMENT**

Alitalo et al. Filing Date 09-23-03 1647

C88	Riess et al., "Transplanted Neural Stem Cells Survive, Differentiate, and Improve Neurological Motor Function After Experimental Traumatuce Brain Injury", Neurosurgery 51: 1043-1054, 2002
C89	Ronnett et al., "Human Cortical Neuronal Cell Line: Establishment from a Patient with Unlateral Megalencephaly", Science 248: 603-605, 1990
C90	Salven et al., "VEGFR-3 and CD133 Identify a Population of CD34+ Lymphatic/Vascular Endothelial Precursor Cells", <i>Blood</i> 101:168-172, 2003
C91	Snyder, "Neural Stem-Like Cells: Developmental Lessons with Therapeutic Potential", <i>The Neuroscientist</i> 4: 408-425, 1998
C92	Snyder et al., "Neural Progenitor Cell Engraftment Corrects Lysosomal Storage Throughout the MPS VII Mouse Brain", <i>Nature</i> 374: 367-370, 1995
C93	Temple, S., "The Development of Neural Stem Cells", Nature 414: 112-117, 2001
C94	Tepper et al., "Endothelial Progenitor Cells: The Promise of Vascular Stem Cells for Plastic Surgery", <i>Plastic and Reconstructive Surgery</i> 111: 846-854, 2003
C95	Turner-Stokes, L., "Reflex Sympathetic Dystrophy – A Complex Regional Pain Syndrome", Disabil Rehabil. 24: 939-947, 2002
C96	Whittemore, et al., "PhysiologicalRelevance and Functional Potential of Central Nervous System-Derived Cell Lines", Mol. Neurobiology 12: 13-38, 1996
C97	Wigle at al., "Prox1 Function is Required for the Development of the Murine Lymphatic System", Cell 98: 769-778, 1999
C98	Wigle et al., "An Essential Role for <i>Prox</i> 1 in the Induction of the Lymphatic Endothelial Cell Phenotype", <i>EMBO J.</i> 21: 1505-1513, 2002

EXAMINER